Organon & Co. Common Stock (NY:OGN)

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

September 14, 2026

Performance

52-Week Range

13.79

5.6952W Low 13.7952W High

1 Week

13.701W Low 13.791W High

Organon & Co. Common Stock (OGN) traded between $5.69 and $13.79 over the past 52 weeks and last traded at $13.79. Over the past week it ranged between $13.70 and $13.79.

Past 12 Months

+0.6%

+0.3%

+2.4%

+135.3%

+90.5%

+30.1%

1W +$0.08

1M +$0.04

3M +$0.32

6M +$7.93

YTD +$6.55

1Y +$3.19

OGN was +30.1% over the past year, +135.3% over six months, +90.5% year to date, +0.6% in the last week.

12 Months vs Market

OGN

+30.1%

DIA

+9.7%

SPY

+16.2%

QQQ

+25.3%

IWM

+13.7%

Over the past 12 months OGN returned +30.1% versus DIA (Dow) +9.7%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +25.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity

2.2M

2.3M

2.7M

5.5M

YTD

5.3M

5.4M

OGN's 3-month average daily volume is 2.7M.

More News

This House of Representative Just Sold Up To $30K In Organon Stock ↗

August 13, 2026

Via Benzinga

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

August 11, 2026

Organon Announces Quarterly Dividend

July 31, 2026

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

July 24, 2026

Organon & Co. Shareholders Clear Sun Pharma Merger Deal ↗

July 23, 2026

Via MarketBeat

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

July 16, 2026

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

July 07, 2026

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

June 24, 2026

From Kahn Swick & Foti, LLC

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

June 22, 2026

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

June 22, 2026

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

June 16, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

June 16, 2026

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

June 10, 2026

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

June 09, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)

June 09, 2026

Organon to Present New Research on Access and Value at ISPOR 2026

May 15, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)

May 14, 2026

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

May 06, 2026

Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders

May 05, 2026

Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders

May 05, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

May 05, 2026

Halper Sadeh LLC is Investigating Whether AVNS, OGN, ESQ, VRE are Obtaining Fair Deals for their Shareholders

May 05, 2026